Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis

Surgical Oncology Clinics of North America

Volumn 12, Issue 3, 2003, Pages 755-769

  Elias, Dominique M ^a   Sideris, Lucas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ABSCESS; ADULT; ARTERY RUPTURE; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG SPECIFICITY; FOLLOW UP; HEATING; HEMOPERITONEUM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIC THERAPY; INTESTINE FISTULA; INTRAOPERATIVE PERIOD; KIDNEY FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; REVIEW; SIDE EFFECT; SUICIDE; SURVIVAL RATE; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

EID: 0041743197     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00051-6     Document Type: Review

References (28)

1. Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994;41:207-13.
2. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254-61.
3. Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437-44.
4. Elias D, Antoun A, Goharin A, El Otmany A, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest 2000;1:431-9.
5. Fujimoto S, Shresta RD, Kokubun M, Kobayashi K, Kiushu S, Konna C, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far advanced gastric cancer. Ann Surg 1990;212:592-6.
6. Hamazoe R, Maeta M, Keibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 1994;73:2048-52.
7. Van der Vaart PJ, van der Vange N, Zoetmulder FA, van Goethtel AR, van Tellingen O, ten Bokkel WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adducts formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-54.
8. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer. J Clin Oncol 1998;16:2739-44.
9. Giachetti S, Perpoint B, Zidani R, Le Bail R, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomoduled fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
10. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
11. Sugarbaker PH, Cunliffe W, Belliveau JF, de Bruin E, Graves T. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988;1:66-79.
12. Sugarbaker PH, Jablonski KH. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-32.
13. Elias D, Gachot B, Bonvalot S, Blot F, Sabourin JC, Ducreux M, et al. Carcinoses péritonéales traitées par exérèse complète et chimiothérapie intra-péritonéale postopératoire immédiate (CIPPI). Etude de phase II portant sur 54 malades. Gastroenterol Clin Biol 1997;21:181-7.
14. Didkhoff T, van der Heider J, Dubbelman R, ten Bokkel Huinink WW. Tissue concentration of platinum after intraperitoneal cisplatin administration in patients. Proc AACR 1985;26:162.
15. Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic Publisher; 1996. p. 155-62.
16. Jacquet P, Elias D, Sugarbaker P. L'implantation tumorale dans les sites de cicatrisation après chirurgie des cancers digestifs. J Chir (Paris) 1996;133:175-82.
17. Rietbroeck RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adducts formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997;123:6-12.
18. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39:2264-8.
19. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221: 29-42.
20. Song CW, Shakil A, Osborn JL, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia 1996;12:367-73.
21. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetic and tissue distribution. Ann Oncol 2002;13:267-72.
22. Misset JL, Gamelin E, Allain P. Pharmacokinetics, urinary and fecal excretion of oxaliplatin in cancer patients. Debiopharm Internal Report; November 1, 1995.
23. Dickson JA. Hyperthermia and laboratory animal systems. In: Proc. Intern. symp. on cancer therapy by hyperthermia and radiation. Washington, DC: Am. Coll. Rad.; 1975. p. 105-6.
24. Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions, after complete resection of peritoneal carcinomatosis. Oncology 2002;63:346-52.
25. Groose E, Walker L, Masters JR. The influence of osmolarity on drug cytotoxicity in vitro. Br J Cancer 1986;54:181-2.
26. Smith E, Brock AP. The effect of reduced osmolarity on platinum drug cytotoxicity. Br J Cancer 1989;59:873-5.
27. Tsujitani S, Oka A, Kondo A, Katano K, Oka S, Saito H, et al. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology 1999;57:77-82.
28. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71-6.